{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:53:10Z","timestamp":1755694390838,"version":"3.40.5"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":150,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.lrr.2024.100466","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T14:54:33Z","timestamp":1718290473000},"page":"100466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A tertiary care centre experience with Elranatamab: A report of three cases"],"prefix":"10.1016","volume":"21","author":[{"given":"Disha","family":"Kakkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakanksha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reshmi Harikumar","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-1302","authenticated-orcid":false,"given":"Tribikram","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy J","family":"Palatty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3100-558X","authenticated-orcid":false,"given":"Rohan","family":"Halder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8743-1801","authenticated-orcid":false,"given":"Narendra","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Bhurani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lrr.2024.100466_bib0001","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transp. J. Am. Soc. Blood Marrow Transp."},{"key":"10.1016\/j.lrr.2024.100466_bib0002","unstructured":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results | Nature Medicine [Internet]. [cited 2023 Oct 28]. Available from: https:\/\/www.nature.com\/articles\/s41591-023-02528-9."},{"key":"10.1016\/j.lrr.2024.100466_bib0003","unstructured":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results | Nature Medicine [Internet]. [cited 2023 Oct 28]. Available from: https:\/\/www.nature.com\/articles\/s41591-023-02528-9."},{"issue":"6","key":"10.1016\/j.lrr.2024.100466_bib0004","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody-drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lrr.2024.100466_bib0005","unstructured":"Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRIL - PMC [Internet]. [cited 2023 Nov 5]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4008386\/."},{"key":"10.1016\/j.lrr.2024.100466_bib0006","unstructured":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma | NEJM [Internet]. [cited 2023 Nov 5]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa2024850."},{"issue":"10297","key":"10.1016\/j.lrr.2024.100466_bib0007","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.lrr.2024.100466_bib0008","unstructured":"Taylor N.P. Fierce Biotech. 2021 [cited 2023 Nov 5]. Pfizer halts BCMA trial amid safety woes, hit by DMD delay. Available from: https:\/\/www.fiercebiotech.com\/biotech\/pfizer-stops-bcma-trial-due-to-adverse-events-reports-dmd-delay."},{"key":"10.1016\/j.lrr.2024.100466_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103453","article-title":"Rethinking mechanisms of neurotoxicity with BCMA directed therapy","volume":"166","author":"Mohyuddin","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048924000566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048924000566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T17:11:41Z","timestamp":1718903501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048924000566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":9,"alternative-id":["S2213048924000566"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2024.100466","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A tertiary care centre experience with Elranatamab: A report of three cases","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2024.100466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100466"}}